REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA

This early-stage study tests a drug called palbociclib, given alone or with other medicines (sorafenib, decitabine, or dexamethasone), in 32 adults whose leukemia has returned or not responded to prior therapy. The main goal is to find the safest dose and check for side effects. …

This study tests a new oral drug (revumenib) combined with chemotherapy in infants and young children up to 6 years old whose leukemia has returned or not responded to treatment. The leukemia must have a specific genetic change called KMT2A rearrangement. The goal is to see if th…

This study tests two drug combinations for adults aged 65 and older with acute lymphoblastic leukemia (ALL). One group gets blinatumomab plus standard chemotherapy; the other gets blinatumomab, dasatinib, and prednisone. The goal is to see if these combos help control the cancer …

This early-stage study tests a new cellular therapy for adults with high-risk acute lymphoblastic leukemia (ALL) that has come back or not responded to treatment. Researchers take a patient's own white blood cells, add a gene to help them recognize and attack cancer cells, and in…

This study tests a combination of low-intensity chemotherapy, a targeted drug called ponatinib, and an immunotherapy called blinatumomab in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), a fast-growing blood cancer. The goal is to see if this app…

This study tests a combination of two drugs, venetoclax and navitoclax, in children whose acute lymphoblastic leukemia has returned or not responded to standard therapy. The goal is to see if this combination can clear the cancer from the bone marrow (called minimal residual dise…

This early-stage study tests a new treatment for adults with acute lymphoblastic leukemia (ALL) that has not responded to chemotherapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The goal is to see i…